Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus Medtech (Hangzhou)VMTHF 52 Debt-to-Equity is 0.04 as of Dec. 2025, which is 76% below its 10-year median of 0.17. GuruFocus rates VMTHF with a GF Score™ of 52/100 and a GF Value™ of $1.27. The stock has 4 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Venus Medtech (Hangzhou) ranks better than 85.55% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Venus Medtech (Hangzhou)'s Debt-to-Equity or its related term are showing as below:
VMTHF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.17 Max: 0.5
Current: 0.04
During the past 9 years, the highest Debt-to-Equity Ratio of Venus Medtech (Hangzhou) was 0.50. The lowest was 0.01. And the median was 0.17.
VMTHF's Debt-to-Equity is ranked better than 85.55% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs VMTHF: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Venus Medtech (Hangzhou) Debt-to-Equity Related Terms
Venus Medtech (Hangzhou) Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) (VMTHF) has a Debt-to-Equity of 0.04 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Venus Medtech (Hangzhou) and its competitors. This is 76% below median its historical median of 0.17. Over the past decade, Venus Medtech (Hangzhou)'s Debt-to-Equity has ranged from 0.01 to 0.50. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #102 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 14.4%.
Is Venus Medtech (Hangzhou)'s Debt-to-Equity too high?
Venus Medtech (Hangzhou)'s current Debt-to-Equity of 0.04 is 76% below median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.50. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Venus Medtech (Hangzhou)'s value of 0.04 is 82.6% below this industry median. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #102 out of 706 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #102 out of 706 companies for Debt-to-Equity. This places Venus Medtech (Hangzhou) in the top 14% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Venus Medtech (Hangzhou)'s value of 0.04 is 82.6% below this benchmark. Historically, Venus Medtech (Hangzhou)'s own Debt-to-Equity has ranged from 0.01 to 0.50 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 0.23, Venus Medtech (Hangzhou) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Medtech (Hangzhou)'s current Debt-to-Equity of 0.04 is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Venus Medtech (Hangzhou) and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current Debt-to-Equity is 0.04, which is 76% below median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current Debt-to-Equity of 0.04. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current Debt-to-Equity is 0.04, which is 76% below median its 10-year median of 0.17 and 82.6% below the Medical Devices & Instruments industry median of 0.23. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current Debt-to-Equity is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.
Key valuation signals for VMTHF:
Debt-to-Equity: 0.04 (76% below median its 10-year median of 0.17)
GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
Industry Position: 82.6% below the Medical Devices & Instruments median (#102 of 706)
No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for VMTHF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMTHF has been successfully added to your 
